Studies on the medical treatment of XXXX .

@entity1 @entity2002 @entity291 @entity548 @entity1150 @entity2786 @entity6805 @entity3479 @entity1909 @entity715 @entity1229
The aim of these studies was to investigate different regimens of thrombolytic therapy and oral anticoagulation, and to evaluate the effects of streptokinase (SK), heparin and @entity1229 in the treatment of @entity1150 ( @entity1150 ). Low-dose SK, although controlled according to the @entity2002 levels, did not provide improved thrombolysis compared to conventional high-dose SK, and more postthrombotic changes were registered after an average of 3 years. Furthermore, serious hemorrhagic side-effects occurred, which makes this regimen inexpedient. Various regimens of local venous infusion of SK were tried, and with a dose of 4,000 IU/h for 72 h in combination with heparin a thrombolytic effect was achieved, albeit not greater than usually observed with conventional SK. Systemic @entity6805 and @entity548 were not avoided. A hitherto not described side-effect with @entity1909 was reported. Venographic severity of @entity291 @entity715 displayed a statistically significant correlation to long-term hemodynamic changes, as assessed with foot volumetry, after an average of 5 years. This correlation was stronger for the size of the @entity715 after initial treatment than for the size at diagnosis. Thus it seems important to treat @entity291 @entity715 with heparin in order to limit the extent of the @entity715 , thereby reducing long-term sequelae. During heparin treatment, an average reduction of the thrombi of 17% was observed. This reduction was significantly correlated to a short duration of symptoms but not to parameters of heparin therapy or fibrinolytic components. However, @entity1 with substantial thrombolysis had high plasmin-alpha 2-antiplasmin ( @entity2786 ) levels, and those with high @entity3479 ) inhibitor levels and remarkably also those with high @entity3479 antigen levels had no lysis. The concentration of @entity3479 antigen showed a significant increase during heparin infusion, whereas that of @entity2786 and @entity3479 inhibitor was not influenced. By applying more intensive initial oral anticoagulation, stable therapeutic prothrombin time (PT)-levels were achieved one day earlier and the duration of heparin infusion could be equally reduced compared to the conventional regimen (4.4-5 days vs 5.4-6 days). The activity of coagulation factors II, VII, IX and X had dropped to the same level with both regimens the day heparin was discontinued, observed. The effectiveness of oral anticoagulation after @entity1150 was studied in 596 @entity1 treated for a total of 4450 months.(ABSTRACT TRUNCATED AT 400 WORDS)
